Loading clinical trials...
Loading clinical trials...
An Open-Label Extension Study of EryDex in Patients With Ataxia Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT)
Conditions
Interventions
Dexamethasone sodium phosphate
Locations
21
United States
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence
Los Angeles, California, United States
The Johns Hopkins Hospital, Division of pediatric allergy and immunology
Baltimore, Maryland, United States
Saint Peter's University Hospital, Inc.
New Brunswick, New Jersey, United States
Cincinnati Children's Hospital, Division of neurology
Cincinnati, Ohio, United States
UT Health Houston, Department of pediatrics, division of child & adolescent neurology
Houston, Texas, United States
Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology
Copenhagen, Denmark, Denmark
Start Date
December 11, 2024
Primary Completion Date
January 30, 2026
Completion Date
January 30, 2026
Last Updated
February 27, 2026
NCT05692596
NCT05252819
NCT04991701
NCT04037189
NCT02285348
Lead Sponsor
Quince Therapeutics S.p.A.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions